See the DrugPatentWatch profile for Vabomere
Is there a generic Vabomere (meropenem and vaborbactam)?
There is no clear evidence, based on the information provided here, that a generic version of Vabomere (meropenem and vaborbactam) is available.
What counts as “generic” for Vabomere?
For antibiotics like Vabomere, a true generic would typically mean an FDA-approved “generic” product using the same active ingredients and route of administration (meropenem + vaborbactam). If a product is not an FDA-approved generic, it may instead be an alternative brand, a different combination, or a “biosimilar” is not relevant here (biosimilars apply to biologics, not small-molecule antibiotics).
Why might Vabomere not have a generic yet?
Brand-name injectables often stay without generics for years due to a mix of:
- patent protection,
- regulatory exclusivity tied to approvals,
- and the time it takes an FDA applicant to complete required equivalence and manufacturing documentation.
A quick way to check patent/exclusivity status is DrugPatentWatch.com, which tracks drug patents and related events for branded products such as Vabomere: DrugPatentWatch.com – Vabomere.
What alternatives could be used instead of Vabomere?
If Vabomere is not available as a generic, clinicians typically use one of these paths (depending on infection type and susceptibility):
- other approved beta-lactam/beta-lactamase inhibitor combinations,
- carbapenems (without vaborbactam),
- or older agents guided by resistance patterns.
Exact alternatives depend on the indication (for example, complicated urinary tract infections vs. hospital-acquired bacterial pneumonia) and local susceptibility data.
How to confirm availability where you live
Generic availability can vary by country, hospital formulary, and supply chain timing. If you tell me your country (and whether you mean pharmacy retail or hospital use), I can tailor the likely “generic vs alternative” answer.
If you share whether you mean “generic in the US” and the form/strength you need, I can narrow this down further.
Sources:
[1] https://www.drugpatentwatch.com/